Microfluidic nanopore platform for high-sensitivity seed health testing
A cutting-edge microfluidic nanopore platform offering amplification-free detection of molecular biomarkers for seed health, adaptable for various targets. This technology enhances RNA detection without false positives, aiding in seed viability assessments.
Overview
The microfluidic nanopore platform developed by Fluxus Technologies represents a breakthrough in high-sensitivity testing for seed health. Utilizing a novel Trapping-Assisted Capture Rate Enhancement (TACRE) principle, this platform allows for amplification-free and label-free detection of single molecular biomarkers at attomolar concentrations. The platform's versatility enables its adaptation to various targets, making it a powerful tool for assessing seed viability by detecting viral RNA, such as TMV, in seeds.
Technical specifications
The platform operates through a two-step process. Initially, specific targets are extracted onto functionalized microbeads. These beads are then trapped under a nanopore within a microfluidic channel. As targets are released from the beads, they are captured and detected as they pass through the nanopore. This method ensures accurate detection without amplification, reducing the risk of false positives. The system has demonstrated effectiveness in detecting viral RNA from Zika and SARS-CoV-2, with potential applications expanded to TMV in seed samples.
Technology readiness level
Currently at Technology Readiness Level 3, this platform has undergone initial proof-of-concept testing. Future plans involve a two-year validation process to refine the technology for commercial application, focusing on developing specific assays for TMV and optimizing RNA extraction protocols. This comprehensive validation will enhance the platform's readiness for widespread use in agricultural health diagnostics.
About Fluxus Technologies
Fluxus is a biotechnology and medical device company specializing in optofluidics and single-molecule counting technologies. Founded in 2016 and based in Sunnyvale, California, the company develops and manufactures biochip-based detection platforms for ultrasensitive diagnostic and bioanalytical applications. Its technology integrates advanced photonics, microfluidics, and assay development to enable precise detection and monitoring of biomarkers. By combining these engineering and scientific disciplines, the company creates systems designed to provide high-sensitivity performance for diverse clinical and research needs.
The company focuses on addressing critical gaps in clinical research and diagnostics, aiming to advance the detection, treatment, and monitoring of diseases. Its solutions are designed for use by clinicians, researchers, and industry partners to improve diagnostic yields. Since its 2022 acquisition, Fluxus has operated as a subsidiary of Fujirebio Holdings, Inc., blending the agility of a startup with the resources of an established multinational organization. Its technology has been applied in the development of assays for various pathogens and conditions, supporting efforts to deliver accurate, high-performance testing tools to healthcare environments.
Inquire about this partnering listing
Industry applications
delivered to your inbox.